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A “human knockout” model to 
investigate the influence of the 
α-actinin-3 protein on exercise-
induced mitochondrial adaptations
i. D. Papadimitriou1,3, N. eynon  1,2, X. Yan1, F. Munson1, M. Jacques  1, J. Kuang1, S. Voisin  1, 
K. n. North2 & D. J. Bishop  1,4
Research in α-actinin-3 knockout mice suggests a novel role for α-actinin-3 as a mediator of cell 
signalling. We took advantage of naturally-occurring human “knockouts” (lacking α-actinin-3 
protein) to investigate the consequences of α-actinin-3 deficiency on exercise-induced changes in 
mitochondrial-related genes and proteins, as well as endurance training adaptations. At baseline, we 
observed a compensatory increase of α-actinin-2 protein in ACTN3 XX (α-actinin-3 deficient; n = 18) 
vs ACTN3 RR (expressing α-actinin-3; n = 19) participants but no differences between genotypes for 
markers of aerobic fitness or mitochondrial content and function. There was a main effect of genotype, 
without an interaction, for RCAN1-4 protein content (a marker of calcineurin activity). However, there 
was no effect of genotype on exercise-induced expression of genes associated with mitochondrial 
biogenesis, nor post-training physiological changes. In contrast to results in mice, loss of α-actinin-3 
is not associated with higher baseline endurance-related phenotypes, or greater adaptations to 
endurance exercise training in humans.
An important component of the skeletal muscle Z-disk in fast-twitch muscle fibres is α-actinin-31, a protein that 
interacts with multiple metabolic, structural, and signalling molecules2. A common polymorphism in the ACTN3 
gene (i.e., the ACTN3 577XX genotype) leads to complete absence of α-actinin-3 protein in the fast-twitch fibres 
of skeletal muscles. This genotype is underrepresented in elite Australian3, Finish4, Greek5, Russian6, Israeli7, 
Polish8, and Japanese9, power-oriented athletes, which suggests α-actinin-3 deficiency has a negative effect on 
the function of fast-twitch muscle fibres10. There are, however, contradicting findings concerning the influence 
of the ACTN3 577XX genotype on endurance performance. Although some studies have reported an association 
between the ACTN3 577XX genotype and endurance status in elite athletes11, others have not12,13.
In contrast to human studies, research in Actn3 knockout mice (Actn3 KO) suggests that the adaptive response 
to endurance training is influenced by the ACTN3 genotype14. After four weeks of endurance training, Actn3 KO 
mice had greater endurance exercise performance and faster recovery from fatigue, compared with wild type 
(WT) mice, and this was associated with a shift in the characteristics of fast-twitch muscle fibres toward a more 
oxidative, slow-twitch phenotype15,16. Seto et al.14 also reported an increase in calcineurin activity (1.9-fold) in 
the muscle of exercised Actn3 KO mice compared with the WT mice (p = 0.093), which was associated with an 
increase (2.9-fold) in the Regulator of Calcineurin (RCAN1-4) protein content17. Consistent with their obser-
vations in mice, there was a also greater protein content of RCAN1-4 in resting muscle samples obtained from 
ACTN3 577XX versus ACTN3 577RR humans14.
The molecular mechanisms underlying the modified calcineurin activity when α-actinin-3 is absent appear 
to be via altered binding of calsarcin-2 to sarcomeric α-actinins. When the α-actinin-3 protein is absent (ACTN3 
577XX) there is a compensatory increase in α-actinin-2, which binds more tightly to calsarcin-2 (a negative 
regulator of calcineurin)18. Thus, absence of α-actinin-3 protein (with a compensatory increase in α-actinin-2) 
has been hypothesised to increase the release and activation of calcineurin14. Activated calcineurin is able to 
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dephosphorylate many substrates, including Nuclear Factor of Activated T-cells (NFAT) - promoting transloca-
tion of this protein to the nucleus19. In the nucleus, NFAT interacts with myocyte enhancer factor-2 (MEF2) to 
regulate expression of peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1α) – often 
described as the “master regulator” of mitochondrial biogenesis20. Compared to WT mice, overexpression of 
activated calcineurin results in a significant increase in electron transport system proteins (complexes I to V)21, 
and a 35% increase in resting mitochondrial respiratory capacity22, and a significant increase in PGC-1α protein 
content23. Altered calcineurin activity therefore provides a plausible biological mechanism for the more “aerobic” 
or “endurance” phenotype in mice that lack α-actinin-3.
Knocking out the ACTN3 gene in mice has provided a useful model to investigate the effects of α-actinin-3 
on skeletal muscle metabolism and associated molecular signalling pathways. Nonetheless, results from KO mice 
don’t always translate to humans and complementary studies in humans remain essential to confirm the findings 
observed in mice. While knocking out genes in humans is ethically off-limits, the high percentage of the human 
population in which the α-actinin-3 protein is absent (i.e., naturally occurring human “knockouts”) affords us the 
unique opportunity to study the consequences of α-actinin-3 deficiency on human skeletal muscle.
Our aim was to investigate the role of the α-actinin-3 protein in regulating metabolism, molecular signal-
ling pathways, and physiological adaptations, in human skeletal muscle at baseline, following one session of 
High-Intensity Interval Exercise (HIIE), and following 4 weeks of High-Intensity Interval Training (HIIT). We 
chose HIIT as it has been reported to be equally or more effective at improving mitochondrial respiratory func-
tion, and increasing the expression of nuclear genes encoding mitochondrial proteins (NUGEMPs), compared to 
moderate-intensity exercise24–26. We hypothesised that humans with the ACTN3 XX genotype (i.e., Actn3 human 
“knockouts”) would have greater endurance performance and higher mitochondrial content and respiratory 
function at baseline compared to their ACTN3 RR counterparts (α-actinin-3 protein is present). We also hypoth-
esised that ACTN3 XX humans would have higher mitochondrial-related gene and protein expression following a 
single session of HIIE, and greater changes in physiological characteristics important for endurance performance 
following four weeks of HIIT, compared to their ACTN3 RR counterparts.
Methods
Study design and participants. More than 100 participants were recruited from the local community. 
Informed consent was obtained prior to a subject’s participation in the research project. The experimental proto-
cols/methods used in this study were approved by the Victoria University Ethics Committee (Ethics Application 
ID: HRE13-223) and carried out based on our standardised protocols27 in accordance with Victoria University 
relevant guidelines, research ethics, and regulations regarding the use of human tissue and DNA samples.
After screening for ACTN3 genotype, only the ACTN3 RR and the ACTN3 XX participants were included in 
this study to ensure we compared the two homozygotic genotypes (i.e., RR vs. XX). Only healthy Caucasians (for 
≥3 generations), with a Body Mass Index (BMI) between 20 and 30 kg•m−2 and a body fat value < 25%, were 
included in the study to ensure both body composition and genetic homogeneity28. Participants with a history 
of any of the following medical conditions were excluded from the study: a significant recurrent or chronic res-
piratory condition, possible coronary heart disease, major musculoskeletal problems or conditions interfering 
with the ability to cycle, uncontrolled metabolic disorders or endocrine disorders, or diabetes requiring insulin.
The calculation of sample size was based on a conservative estimate of both the expected change and the 
standard deviation for exercise-induced changes in PGC-1α mRNA (derived from our previous work). The sam-
ple size necessary to achieve statistical significance between groups (using an alpha of 0.05 and a power of at least 
0.80) was 15 participants for each group. To account for the possibility of drop outs, we aimed to recruit at least 
18 participants for each group.
Thirty-seven (n = 19 ACTN3 RR, and n = 18 ACTN3 XX) moderately-trained (VO2 peak 35 to 
60 mL•min−1•kg−1) men, with a BMI of 26.6 ± 2.6 for RR and a BMI of 24.2 ± 2.4 for XX, with a mean age 
32.2 ± 7.1 years for RR and 29.4 ± 8.4 years for XX, were subsequently included in our study population.
Genotyping. Genomic DNA was extracted from fingertip blood samples obtained from the graded exercise 
tests (GXT) using the GeneJET Genomic Whole Blood DNA Purification Kit (#K0781 Thermo Scientific, MA, 
USA). ACTN3 gene variants were determined in duplicate using the TaqMan SNP assay (Applied Biosystems, 
Thermo Fisher Scientific, CA, USA) by Mastercycler® ep realplex2 (Eppendorf, Hamburg, Germany). Genotyping 
was replicated in another independent institute (The Murdoch Childrens Research Institute, Melbourne), as pre-
viously described29, to validate the results.
Pre-training physical activity monitoring. To determine if there were any fluctuations in habitual phys-
ical activity between participants, 1 week prior to commencing the study the participants’ activity levels were 
monitored for one week. The monitoring of each participant’s activity level was performed using an ActiGraph 
GT3X + device (ActiGraph LLC, Fort Walton Beach, FL, USA). The GT3X + activity monitor has been used in 
many types of and clinical applications30 and research31. The activity monitor includes a micro-electro-mechanical 
system based tri-axis accelerometer sensor that provides measures of acceleration in three axes, with a composite 
measure called the vector magnitude (VM = √(x2 + y2 + z2)). The accelerometer has a ±6 g range, with a sam-
pling rate ranging from 30 Hz to 100 Hz (user selectable), and stores the raw, non-filtered/accumulated data in 
the units of gravity. The activity monitor can sample continuously for between 24 and 32 days depending on the 
selected sampling frequency.
The ActiGraph GT3X+ device was worn either over or under clothing, which ever was most comfortable for 
the participant and threaded onto an elastic belt. The device was positioned snugly enough against the body so 
that it could not flip around. The accelerometer was worn with the elastic belt fastened around the waist over the 
right hip bone all day while the participant was awake. The device was removed only when the participant was in 
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bed at night, showering, or swimming. A daily diary assisted in monitoring when the device was removed or if 
any water-based activities were performed. The acceleration data were downloaded from the activity monitor and 
processed over a user-specified time sampling interval. Activity intensity and energy expenditure was calculated 
using algorithms that have been used in other similar studies32.
Nutrition consultation. To ensure similar nutrition between participants, each participant was provided 
with individualised, pre-packaged meals for the 48 hours prior to all resting muscle biopsies and standardised 
nutrition (composed of mainly liquids and carbohydrates) before and after each training session during the 
4-week training period. The energy content of the provided meals was calculated using the participant’s body 
mass, the Mifflin-St-Jeor equation, and the participant’s, age, and height33. The Foodworks (Xyris) nutritional 
database was used to determine the nutritional components of the packaged meals and to ensure all nutritional 
requirements were met with the diet. The content of the diets was constructed based on the current Medical 
Research Council (NHMRC) and National Health guidelines. To ensure adequate access to carbohydrate 
energy stores, participants were asked to consume a pre-packaged training meal of high glucose food items (1 to 
1.5 g•kg−1 BM) 2 hours prior to the commencement of each testing session, according to Australian Institute of 
Sport (AIS) guidelines (https://www.ausport.gov.au/ais/sports_nutrition), composed of mainly liquids and car-
bohydrates. Participants were also asked to refrain from caffeine and alcohol during the dietary control period, 
which was 48 hours prior to all biopsies.
Performance tests. Prior to the start of the exercise intervention phase, all participants completed familiar-
isation sessions and baseline testing. All visits were separated by a minimum of 48 hours. In addition, participants 
were required to refrain from alcohol, caffeine consumption, and any form of physical activity, for 24 hours before 
all performance tests. The familiarisation and baseline testing consisted of the following27:
 1. 20-km cycle Time Trial (20k-TT) – The 20k-TT test was performed on a Velotron® stationary cycle er-
gometer (RacerMate Inc. Seattle, WA, USA). Participants completed a warm-up consisting of 5 minutes of 
cycling at 60 W. Following a 2-minute rest, participants were then required to complete the 20-k TT in the 
quickest possible time. Participants were permitted to monitor their progress through completed distance 
and were provided with verbal encouragement during the test.
 2. Graded exercise test to exhaustion (GXT) – The GXT was performed on an electronically-braked cycle 
ergometer (Lode-Excalibur sport, Groningen, the Netherlands) and consisted of 4-min stages of increasing 
intensity, separated by 30-s rest periods, until exhaustion34. The test started at 60, 90, or 120 W (depending 
on the participant’s 20k-TT results) and increased by 30 W in each subsequent stage. For the participants 
who did not complete the final stage, peak power (Wpeak) was calculated based on power achieved at the 
point of exhaustion. Fingertip samples were taken at rest, after each completed stage, and immediately 
following exhaustion, and were analysed by a YSI 2300 STAT Plus system (Yellow Springs, Ohio, USA). The 
LT was then calculated using the modified Dmax method, which is determined by the point on the polyno-
mial regression curve that yields the maximum perpendicular distance to the straight line connecting the 
first increase in lactate concentration above the resting value and the final lactate point35. The average of 
the two baseline GXT tests was recorded as the baseline value and was also used to customise subsequent 
exercise intensities if the difference was no more than 5%; otherwise, the highest value was used. Residual 
capillary blood samples were saved for DNA analysis27.
 3. VO2peak test - After five minutes of rest following each GXT, peak oxygen consumption (VO2peak) was meas-
ured using a calibrated Quark CPET metabolic system (COSMED, Rome, Italy). Briefly, participants wore 
the Cosmed face mask and exercised to exhaustion at 105% of the Wpeak measured during the previous 
GXT. The VO2peak was considered the highest value in 1 minute obtained during the test, and the average 
of the two baseline tests was recorded as the baseline value. Previous studies have reported the VO2peak 
measured this way is not different from that derived from a ramp test36.
Muscle biopsies and high-intensity interval exercise (HIIE). Forty-eight to 72 hours after the last 
VO2peak test, muscle biopsies were collected from the vastus lateralis muscle of the participant’s dominant leg. 
Following injection of a local anaesthetic (5 mL, 1% Xylocaine), incisions were made and the biopsy needle was 
inserted. Muscle samples were collected with manual suction applied37. The samples (50 to 200 mg) were then 
immediately blotted on filter paper to remove excess blood, and a small portion (5 to 15 mg) was immediately 
processed for the determination of mitochondrial respiration in SITU38; the remaining muscle was snap frozen 
in liquid nitrogen before being stored at −80 °C for further analyses. Following the pre-training baseline muscle 
biopsy, participants performed a single session of HIIE on an electronically-braked cycle ergometer (Velotron®, 
Racer Mate Inc, Seattle, USA). The session consisted of eight 2-minute intervals performed at an intensity 
between the individually-determined pre-training LT power and Wpeak (LT + 40% × [Wpeak − LT)), which were 
interspersed with 1-minute recovery periods at 60 W (work-to-rest ratio of 2:1). All participants were motivated 
and reached the expected loads during all eight 2-minute intervals. Muscle biopsy samples were also taken imme-
diately after and 3 hours post the HIIE session27.
High intensity interval training (HIIT) phase. Two days after the collection of muscle biopsies, partici-
pants were required to train 3 times per week for 4 weeks (12 sessions including the HIIE session with biopsies) 
(Fig. 1). All training sessions where completed on an electronically-braked cycle ergometer (Velotron®, Racer 
Mate Inc., Seattle, USA). Each session consisted of six to fourteen 2-min intervals performed at intensities rang-
ing from LT + 40% × [Wpeak − LT] (week 1) to LT + 70% × [Wpeak − LT] (week 4), and interspersed with 1-min 
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recovery periods at 60 W (work- to-rest ratio of 2:1). In order to maintain progression, there were a different 
numbers of bouts per session (as shown in Fig. 1).
Post-training performance tests. At the completion of training, post-training GXTs and VO2peak tests 
took place at the same time of day as pre-training to assess changes in Wpeak and LT (Fig. 1). The average of the two 
GXT tests was used to determine the influence of training on common physiological determinants of endurance 
performance if the difference was less than 5%. If the difference between the results of the two tests was larger 
than 5%, the highest value was used. During a second visit the participants performed a post-training 20K-TT test 
to assess improvements in endurance performance (Fig. 1)27.
RNA extraction and gene expression analysis. Total RNA was extracted from approximately 15 mg 
of frozen muscle. Cellular membranes were dissociated in TRIzol® Reagent (Invitrogen, Melbourne, Australia) 
through TissueLyser II (Qiagen, Hilden, Germany) for 2 × 1 minute at 30 Hz. The homogenate was centrifuged 
(13,000 RPM for 15 minutes) and the RNA containing supernatant removed. The homogenate then was com-
bined with chloroform (Sigma-Aldrich, St Louis, USA) and total tissue RNA was then extracted using the TRIzol 
protocol according to the manufacturer’s instructions, with the exception of RNA precipitation which was con-
ducted for a minimum of 2 hours at −20 °C in the presence of 10 µL of 5 M sodium chloride. RNA purity was 
checked using the ratio of its absorbance at 260 and 280 nm using a BioSpectrometer (Eppendorf, Hamburg, 
Germany) and concentration was quantified spectrophotometrically at 260 nm. First strand cDNA was then 
generated from 1 µg of template RNA using the commercially available iScript™ cDNA synthesis kit (Bio-Rad 
Laboratories, Hercules, USA) using random hexamers and oligo dTs according to the protocol provided with the 
iScipt cDNA synthesis kit (Bio-Rad Laboratories, Hercules, USA). cDNA was stored at −20 °C for subsequent 
analysis. All samples and reverse transcriptase (RT) negative controls were run together to prevent technical 
variation. Forward and reverse primers for the target and housekeeping genes were designed based on NCBI 
RefSeq using NCBI Primer-BLAST (www.ncbi.nlm.nih.gov/BLAST/) (Table 1). Specificity of the amplified prod-
uct was confirmed by melting point dissociation curves generated by the PCR instrument. The mRNA expression 
of housekeeping and target genes were quantified by quantitative real-time RT-PCR (QuantStudioTM 7 Flex 
Real-Time PCR System (Life Technologies, Thermo Fisher Scientific, Wilmington, DE, USA), using a 5 µL PCR 
reaction volume and SYBR® Green chemistry (iTaqTM Universal SYBR® Green Supermix, Bio-Rad, Hercules, 
CA). All samples were run in duplicate simultaneously with template free controls, using an automated pipetting 
system (epMotion 5073, Eppendorf, Hamburg, Germany). The following PCR cycling patterns were used: initial 
denaturation at 95 °C for 3 min, 40 cycles of 95 °C for 15 s and 60 °C for 60 s.
Western blot for protein content. Approximately 10 mg of frozen muscle samples were homogenised 
in ice-cold RadioImmunoPrecipitation Assay (RIPA) lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5% 
Sodium Deoxycholate, 1% Triton X-100, 0.1% SDS, 1 mM EDTA with protease/phosphatase inhibitors, 1 mM 
PMSF, 1 g/mL Aprotinin, 1 g/ml Leupeptin, 1 mM Benzamidine, 1 mM Na3VO4, 5 mM Na Pyrophosphate, 1 mM 
DTT and 1 mM NaF) using a TissueLyser II (Qiagen, Hilden, Germany) for 2 × 1 minute at 30 Hz, and rotated for 
1 h at 4 °C. Muscle lysates were stored at −80 °C until further analysis. Total protein content of muscle lysates was 
determined using the bicinchoninic acid assay.
Figure 1. Study overview. 20k-TTfam: 20 kilometre time-trial familiarisation; 20k-TT: 20 kilometre time trial; 
GXTfam: graded exercise test familiarisation; GXT: graded exercise test; LT: Power at the Lactate Threshold, 
Wpeak: peak power achieved during the GXT, Δ: difference between Wpeak and LT; The periodisation of 
training ranged from 9 bouts of HIIE at LT + 40%Δ in the first week (green line), to one peak of 12 bouts at 
LT + 50%Δ in the second week (blue line), and one higher peak of 14 bouts at LT + 60%Δ in the third week. 
The intensity increased to LT + 70%Δ in the fourth week, with a reduction in the number of bouts to 6 at the 
end of this last week (brown line) - this served as taper period. mRNA: messenger RNA.
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Protein extracts were loaded on sodium dodecyl sulfate-polyacrylamide gels, separated for 120 minutes 
at 100 V and subsequently transferred to PolyVinyl DiFluoride (PVDF) membranes (Bio-Rad Laboratories, 
Hercules, USA) using a Bio-Rad blot system for 100 minutes at 100 V. Thereafter, blots were blocked for 60 min-
utes in 5% milk in tris-buffered saline (TBS) and washed with TBS plus 0.1% Tween at room temperature, fol-
lowed by incubation with different primary antibodies overnight at 4 °C. After washing, the membranes were 
incubated with the appropriate secondary antibodies for 60 minutes at room temperature and revealed using a 
chemiluminescent substrate (Bio-Rad Laboratories, Hercules, USA). The primary antibodies were ACTN3 (a 
kind gift from Professor Kathryn North), ACTN2 (Ab68168, Abcam, Cambridge, United Kingdom), PGC-1α 
(#2178, Cell Signaling, Danvers, Massachusetts, United States), RCAN1 (D6694, Sigma-Aldrich, St. Louis, 
Missouri, United States), Calsarcin 2 (Ab197660, Abcam). All primary antibodies were diluted 1:1000 in 5% 
BSA. The secondary antibodies were purchased from Perkin Elmer (Waltham, Massachusetts, USA) and diluted 
1:10000 in 5% skim milk (Goat Anti-Mouse IgG (NEF822001EA), Goat Anti-Rabbit IgG (NEF812001EA)). Light 
emission was recorded using ChemiDocTM MP System (Bio-Rad Laboratories, Hercules, USA) and quantified 
by image analysis software (Image Lab, Bio-Rad). Protein content was then normalised to totally protein analysis 
by TGX stain-free gel (Bio-Rad Laboratories, Hercules, USA)39.
Mitochondrial respiration and citrate synthase. Immediately after the resting biopsy, muscle fibres 
were separated gently on ice under a binocular microscope in BIOPS solution (2.77 mM CaK2EGTA, 7.23 mM 
K2EGTA, 5.77 mM Na2ATP, 6.56 mM MgCl26•H2O, 20 mM Taurine, 15 mM Na2Phosphocreatine, 20 mM 
Imidazole, 0.5 mM Dithiothreitol, and 50 mM MES at PH7.1), and permeabilised in the same solution with 
50 μg/mL of saponin (Sigma-Aldrich, St Louis, USA) for 30 minutes. This was followed by rinsing the muscle 
fibres for 3 × 7 minutes in mitochondrial respiration medium on ice (0.5 mM EGTA, 3 mM MgCl2•6H2O, 60 
mM K-lactobionat, 20 mM Taurine, 10 mM KH2PO4, 20 mM Hepes, 110 mM sucrose, and 1 g•L−1 bovine serum 
albumin at pH 7.1). Experiments were performed on washed muscle fibres under continuous stirring using 
an oxygraph-2k respirometer (Oroboros Instruments, Austria), containing 2 mL of mitochondrial respiration 
medium with additional substrates at 37 °C. The following substrates were added (final concentration): malate 
(2 mM) and pyruvate (5 mM) to support electron entry to complex I (CI); MgCl2 (3 mM) and ADP (5 mM) to 
measure Oxidative phosphorylation (OXPHOS) capacity; Succinate (10 mM) to stimulate CI + II-linked respira-
tion and provide convergent electron input into the Q-junction simultaneously (CI + IIP)40. A maximal respira-
tory capacity is reached when these substrates are present in the respirometer chamber. Cytochrome c (10 µM) 
was used to test the integrity of the outer mitochondrial membrane31. Electron transfer system capacity (ETS with 
CI + II-linked substrates, CI + IIE) was tested by titrating p-trifluoromethoxy phenylhydrazone (FCCP) (steps 
of 0.5 µM) until maximal noncoupled respiration was reached. Rotenone (0.5 µM) was then added to block the 
activity of complex so that electrons could only enter through complex II (CII). Antimycin (3.75 µM) was added 
to block the activity of complex III and to measure the non-mitochondrial respiration. Different ratios (substrate 
and coupling control ratios) were calculated from the different titration steps obtained from the protocol used.
Gene Forward Sequence Reverse Sequence
PGC-1α 5′-CAGCCTCTTTGCCCAGATCTT-3′ 5′-TCACTGCACCACTTGAGTCCAC-3′
PGC-1α1 5′-ATGGAGTGACATCGAGTGTGCT-3′ 5′-GAGTCCACCCAGAAAGCTGT-3′
PGC-1α4 5′-TCACACCAAACCCACAGAGA-3′ 5′-TCACACCAAACCCACAGAGA-3′
COX4-1 5′-GAGCAATTTCCACCTCTGC-3′ 5′-CAGGAGGCCTTCTCCTTCTC-3′
NDUFB3 5′-TCAGATTGCTGTCAGACATGG-3′ 5′-TGGTGTCCCTTCTATCTTCCA-3′
SDHB 5′-AAATGTGGCCCCATGGTATTG-3′ 5′-AGAGCCACAGATGCCTTCTCTG-3′
PDK4 5′-GCAGCTACTGGACTTTGGTT-3′ 5′-GCGAGTCTCACAGGCAATTC-3′
MFN2 5′-CCCCCTTGTCTTTATGCTGATGTT-3′ 5′-TTTTGGGAGAGGTGTTGCTTATTTC-3′
RCAN1-4 5′-GGGTCTGTAGCGCTTTCACT-3′ 5′-GGACTCAAATTTGGCCCTGG-3′
SOD-1 5′-GGTCCTCACTTTAATCCTCTAT-3′ 5′-CATCTTTGTCAGCAGTCACATT-3′
HSP70 5′-GGGCCTTTCCAAGATTGCTG-3′ 5′-TGCAAACACAGGAAATTGAGAACT-3′
VEGF 5′-ACAACAAATGTGAATGCAGACCAA-3′ 5′-CGTTTTTGCCCCTTTCCCTT-3′
GAPDH 5′-AATCCCATCACCATCTTCCA-3′ 5′-TGGACTCCACGACGTACTCA-3′
B2M 5′-TGCTGTCTCCATGTTTGATGTATCT-3′ 5′-TCTCTGCTCCCCACCTCTAAGT-3′
TBP 5′-CAGTGACCCAGCAGCATCACT-3′ 5′-AGGCCAAGCCCTGAGCGTAA-3′
Cyclophilin 5′-GTCAACCCCACCGTGTTCTTC-3′ 5′-TTTCTGCTGTCTTTGGGACCTTG-3′
18S 5′-CTTAGAGGGACAAGTGGCG-3′ 5′-GGACATCTAAGGGCATCACA-3′
ACTB 5′-GAGCACAGAGCCTCGCCTTT-3′ 5′-TCATCATCCATGGTGAGCTGGC-3′
Table 1. Details of PCR primers used for RT-qPCR. PGC-1α, peroxisome proliferator-activated receptor-ɣ 
coactivator 1α; COX4-1, cytochrome c oxidase subunit 4I1; NDUFB3, NADH:ubiquinone oxidoreductase 
subunit B3; SDHB, succinate dehydrogenase complex iron sulfur subunit B; PDK4, pyruvate dehydrogenase 
kinase 4; MFN2, mitofusin 2; RCAN1-4, regulator of calcineurin 1-4; SOD-1, superoxide dismutase 1; HSP-
70, heat shock protein family A (Hsp70) member 4; VEGF, vascular endothelial growth factor A; GAPDH, 
glyceraldehyde 3-phosphate dehydrogenase; B2M, β-2-microglobulin; TBP, TATA-box binding protein; 
Cyclophilin, peptidylprolyl isomerase A; 18S, 18S ribosomal RNA; ACTB, actin beta.
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CS activity was determined spectrophotometrically at 30 °C by measuring the appearance of the CoA-SH38.
The reaction was carried out in 100 mM Tris buffer buffer with 0.48 mM acetyl CoA and 0.1 mM 5,59-dithiobis 
(2-nitrobenzoic acid) (pH 8.3). CS activity was determined in triplicate on a microtiter plate by adding muscle 
homogenate. After addition of oxaloacetic acid to final concentration of 0.6 mM, the plate was immediately placed 
in an xMark-Microplate spectrophotometer (Bio-Rad) at 30 °C, and after 30 s of linear agitation, absorbance at 
412 nm was recorded every 15 s for 3 min. CS activity were expressed as moles per hour per kilogram protein.
Statistical analysis. The quantitative genetic association data, mRNA content, protein relative abundance, 
and maximal mitochondrial respiration data were analysed using linear mixed models, with time point (baseline, 
post, 3 h post or pre- and post-training) and genotype (RR or XX) as covariates. The interaction between time 
and genotype was also tested. To test the effect of each covariate (time, genotype or time:genotype), a full model 
containing all covariates was compared with a null model missing the covariate of interest, using a likelihood 
ratio test. All data analyses were conducted with the R statistical software with the lme4 and lrtest packages. The 
significance for all tests was set at 5% (p-value < 0.05).
Results
Genotyping. Genotyping was performed in duplicate and verified by blotting for the α-actinin-3 protein 
(Fig. 2a). As shown in the representative blots, the α-actinin-3 protein was present in ACTN3 RR and not ACTN3 
XX participants. There was also a compensatory greater α-actinin-2 protein content in ACTN3 XX vs ACTN3 RR 
participants (p = 0.018), as shown in the representative images (Fig. 2a) and summarised in Fig. 2b.
Baseline habitual physical activity. There were no significant differences for habitual physical activity 
measured for seven consecutive days, 1 week prior to commencing the study, between ACTN3 XX and ACTN3 RR 
participants (790.2 ± 382.5 Kcal per day for ACTN3 RR vs. 673.9 ± 343.2 Kcal per day for ACTN3 XX genotypes; 
p = 0.37).
Figure 2. (a) Representative images of α-actinin-2 and α-actinin-3 protein content in ACTN3 RR vs. ACTN3 
XX participants at baseline. α-actinin-3 protein was present in ACTN3 RR and not in ACTN3 XX participants. 
(b) Box blot displaying α-actinin-2 protein content in ACTN3 RR vs. XX participants at baseline. There was 
a compensatory greater ACTN2 protein content in ACTN3 XX vs ACTN3 RR participants (p = 0.018). The 
centre rectangle includes the mean and the interquartile range (IQR). The “whiskers” above and below the box 
show the locations of the maximum and minimum values (excluding outliers – defined as ≥0.15 × IQR above 
the third quartile or below the first quartile and indicated by an unfilled circle). *Significant difference between 
genotypes (p < 0.05).
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Baseline physiological characteristics. There were no significant differences for the LT, VO2peak, Wpeak, 
20-k TT performance, citrate synthase activity, or maximal mitochondrial respiration, between ACTN3 XX and 
ACTN3 RR participants at baseline (Table 2).
RCAN 1-4 protein content before and after a single session of HIIE. Resting calsarcin-2 content was 
similar between ACTN3 RR and ACTN3 XX (Fig. 3a). There was a main effect of genotype for RCAN 1-4 protein 
content (P = 0.004), with greater RCAN1-4 protein content in the muscle of ACTN3 577XX versus ACTN3 577RR 
humans (1.3 fold; P = 0.004). Despite the main effect of genotype for RCAN1-4 content, there was no significant 
interaction between genotype and the time at which the baseline biopsy was taken relative to the HIIE session 
(p = 0.12) (Fig. 3b).
Phenotype
Genotype
RR (n = 19) XX (n = 18)
Lactate Threshold (W) 210.4 (52) 196.7 (65.9)
VO2 peak (mL•min−1•kg−1) 43.3 (6.2) 46.9 (6.6)
Lactate Threshold as a percent of Power Peak (%) 71.6 (5.7) 67.8 (7.4)
Peak Power (Wpeak) 291.4 (57.6) 272.1 (70.3)
Time-Trial Performance (s) 2246 (311) 2377.5 (301)
Mitochondrial Respiration
(pmol O2/s−1·mg wet weight−1)
111.1 (35.7) 112.3. (37.3)
Citrate synthase activity
(mol·h−1 · kg protein−1) 13.9 (3.3) 13.0 (4.0)
Table 2. Endurance-related phenotypes measured at baseline: Lactate threshold, VO2peak, Wpeak, 20-km Time-
trial performance, Mitochondrial respiration, and Citrate synthase activity for the two ACTN3 genotypes 
(n = 37). Values are reported as Mean (SD). No significant difference was demonstrated between RR and XX 
genotypes for any of these phenotypes (p > 0.05).
Figure 3. (a) Representative images of calsarcin-2 protein content in ACTN3 RR vs. ACTN3 XX participants 
at baseline. Calsarcin-2 protein content did not differ between muscle samples obtained from ACTN3 XX 
and ACTN3 RR humans (b) A main effect of genotype for RCAN 1-4 protein content was demonstrated, but 
there was no significant interaction effect. Box blot displaying RCAN1-4 protein content in ACTN3 RR vs. XX 
participants. RCAN 1-4 protein content is in arbitrary units (a.u.). The centre rectangle includes the mean and 
the interquartile range (IQR). The “whiskers” above and below the box show the locations of the maximum and 
minimum (excluding outliers – defined as ≥0.15 × IQR above the third quartile or below the first quartile and 
indicated by an unfilled circle).
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The influence of α-actinin-3 deficiency on mitochondrial-related gene expression. The results 
for PGC-1α total, PGC-1α-1, and PGC-1α-4 gene expression are illustrated in Fig. 4. Although there was a main 
effect of exercise for all three PGC-1α gene transcripts, there was no main effect of genotype and no interac-
tion effect. Gene expression analyses of COX-1, RCAN 1-4, HSP70, VEGF, PDK4, SOD-1, MFN2, SDHB and 
NUDFB3 immediately post and 3 h post exercise are shown in Table 2. Again, there was no evidence for any 
Figure 4. Log fold change from baseline to 3 h post exercise for RR and XX participants for: (a) PGC-1α-1 
mRNA expression. P-values: for exercise < 0.05, for genotype = 0.39, and for interaction (exercise × 
genotype) = 0.58 (b) PGC-1α-4 mRNA expression. P-values: for exercise < 0.05, for genotype = 0.25, and for 
interaction (exercise × genotype) = 0.13 and (c) total PGC-1α mRNA expression. P-values: for exercise <0.05, 
for genotype = 0.76, for the interaction (exercise × genotype) = 0.36. Box blot displaying PGC1α-1 mRNA 
values in ACTN3 RR vs. XX participants. The centre rectangle includes the mean and the interquartile range 
(IQR). The “whiskers” above and below the box show the locations of the maximum and minimum (excluding 
outliers – defined as ≥0.15 × IQR above the third quartile or below the first quartile and indicated by an 
unfilled circle).
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difference between ACTN3 XX and ACTN3 RR genotypes, although there were significant time effects (p < 0.05) 
for some of the tested genes (COX-1, RCAN 1-4, HSP70, VEGF and PDK4) (Table 3).
PGC-1α Protein expression in ACTN3 RR and XX humans. PGC-1α total protein was significantly 
increased after HIIE (p-value for exercise < 0.001). However, there was no significant main effect of genotype 
(p = 0.49), and no significant interaction effect (p = 0.77) (Fig. 5).
Training-induced changes in endurance-related phenotypes. Consistent with our pre-training 
measurements, there were no main effects of training or significant differences for the LT, VO2peak, Wpeak, or 
time-trial performance (Table 4) between ACTN3 XX and ACTN3 RR participants after 4 weeks of completing 
the same high intensity interval training (Fig. 6).
Discussion
The high percentage of the population who are deficient for the α-actinin-3 protein has allowed us to employ a 
unique “human knockout” model to investigate the influence of α-actinin-3 protein on baseline endurance char-
acteristics, as well as the response to both a single exercise session and four weeks of exercise training. Following 
the initial screening, we included 19 ACTN3 RR and 18 ACTN3 XX participants into the main study. In addition 
to genotyping in duplicate, we confirmed that the α-actinin-3 protein was present in ACTN3 RR and not ACTN3 
XX participants. At baseline, absence of the α-actinin-3 protein was accompanied by a compensatory increase in 
α-actinin-2 protein content in ACTN3 XX vs ACTN3 RR humans. There was, however, no evidence for significant 
differences in physiological characteristics, or endurance-related phenotypes and mitochondrial characteristics, 
between ACTN3 XX and ACTN3 RR participants. While there was a main effect of genotype for RCAN1-4 pro-
tein content, there was no significant interaction effect for exercise-induced changes in any of the measured genes 
or proteins associated with mitochondrial biogenesis. Consistent with our results for exercise-induced changes in 
mRNA, absence of α-actinin-3 protein has no influence on the response to training for any of the physiological or 
mitochondrial characteristics accessed. Thus, in contrast to studies in mice, absence of ACTN3 protein in humans 
does not influence the response to a single session of endurance exercise or exercise training.
The influence of the ACTN3 gene on physiological parameters at baseline. There were no sig-
nificant differences in the lactate threshold, VO2peak, WPeak, cycling time-trial performance, CS activity, or max-
imal ADP-stimulated mitochondrial respiration, between ACTN3 XX and ACTN3 RR humans (Table 2). These 
variables were chosen as both VO2peak and the lactate threshold have been reported to be important determi-
nants of endurance performance35,41. Mitochondrial respiration and CS activity have also been associated with 
endurance performance in humans24. However, our results indicate there is no influence of the ACTN3 pol-
ymorphism on any of these key endurance phenotypes at baseline. When we repeated the assessments after 
four weeks of high-intensity interval training, we also observed no influence of the ACTN3 polymorphism on 
these endurance-related phenotypes. These findings are in line with the results from a large case-control study12, 
cross-sectional studies42–45 recent meta-analyses46–48 and our quantitative analysis13 that also found no evidence of 
an association between the ACTN3 polymorphism and endurance-related phenotypes in humans.
Gene
ACTN3 
Genotype
Pre 
Exercise
Post 
Exercise
+3 h 
Exercise
MFN2 C
RR n = 19 3.57 (1.63) 3.21 (1.70) 3.65 (1.78)
XX n = 18 3.66 (1.28) 3.32 (1.57) 4.22 (1.95)
COX4-1
RR n = 14 5.11 (3.12) 4.44 (2.82) 4.32 (2.54)
XX n = 13 4.59 (2.04) 4.14 (2.68) 5.08 (2.51)
RCAN1-4*
RR n = 14 0.72 (0.42) 0.69 (0.31) 1.20 (0.96)
XX n = 13 1.06 (0.96) 0.96 (0.73) 1.32 (2.07)
SDHB
RR n = 14 1.04 (0.56) 0.84 (0.26) 0.98 (0.46)
XX n = 13 0.74 (0.54) 0.73 (0.53) 0.78 (0.38)
SOD-1
RR n = 14 0.97 (0.50) 0.90 (0.23) 0.92 (0.29)
XX n = 13 0.67 (0.40) 0.69 (0.31) 0.69 (0.25)
PDK4*
RR n = 14 1.59 (1.21) 2.25 (1.57) 9.63 (5.50)
XX n = 13 2.18 (1.61) 4.00 (3.81) 9.79 (6.53)
HSP70*
RR n = 14 1.27 (0.53) 2.56 (0.99) 3.55 (2.22)
XX n = 13 1.02 (0.42) 1.99 (1.26) 2.95 (1.68)
VEGF*
RR n = 14 0.64 (0.20) 0.57 (0.23) 1.19 (0.45)
XX n = 13 0.46 (0.19) 0.64 (0.64) 0.96 (0.30)
NUDFB3
RR n = 14 1.48 (0.53) 1.91 (0.58) 1.71 (0.55)
XX n = 13 1.15 (0.66) 1.42 (0.60) 1.39 (0.68)
Table 3. Gene expression in arbitrary units (a.u.) for COX4-1, MFN2 C, RCAN1-4, SDHB, SOD-1, PDK4, 
HSP70, VEGF and NUDFB3. Values in parentheses represent the mean ± SEM. There were no significant 
genotype effects for any of these genes (p < 0.05). *Significant time effect (p < 0.05).
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The influence of ACTN3 gene on the protein content of calsarcin-2 & RCAN1-4. It has been 
suggested that the molecular basis for the effects of α-actinin-3 deficiency on muscle properties may be related 
to the activity of calcineurin, which indirectly associates with sarcomeric α-actinins at the Z-disk14. It is well 
established that calcineurin signalling induces activation of the slow myogenic program and a shift in muscle fibre 
attributes toward a slower, more oxidative phenotype14. RCAN1-4 is a downstream target of calcineurin, which 
is increased upon activation by calcineurin and provides a sensitive, indirect measure of calcineurin activity18,49. 
Consistent with the results in mice14, there was a main effect of genotype for RCAN1-4 protein content (ACTN3 
XX > ACTN3 RR; P = 0.004). To assess whether the elevated RCAN 1-4 content in ACTN3 XX humans could be 
attributed to differential expression of calsarcin-2 (which inhibits calcineurin activity50), the content of calsarcin-2 
expression was also measured. Consistent with observations in mice14, the expression of calsarcin-2 did not differ 
between muscle samples obtained from ACTN3 XX and ACTN3 RR humans and therefore does not account for 
the increased RCAN1-4 protein content associated with α-actinin-3 deficiency.
Figure 5. Log fold change from baseline to 3 h post exercise for PGC 1-a protein content in the muscle of RR 
and XX partitipants (3 h post exercise/pre exercise). Box blot displaying PGC1α-1 relative protein abundance in 
ACTN3 RR vs. XX participants. The centre rectangle includes the mean and the interquartile range (IQR). The 
“whiskers” above and below the box show the locations of the maximum and minimum (excluding outliers – 
defined as ≥0.15 × IQR above the third quartile or below the first quartile and indicated by an unfilled circle).
Phenotype
Genotype
RR (n = 19) XX (n = 18)
Lactate Threshold (W) 227.9 (57.2) 213.4 (74.0)
VO2 peak (mL•min−1•kg−1) 46.1 (7.6) 48.4 (7.1)
Lactate Threshold as % of Power Peak (%) 73.1 (5.6) 72.7 (7.3)
Power Peak (Wpeak) 309.2 (63.1) 288.6 (76.4)
Time-Trial Performance (s) 2167 (242) 2242 (231)
Mitochondrial Respiration
(pmol O2/s−1 ·mg wet weight−1)
118.2 (26.4) 116.9 (29.7)
Citrate synthase activity
(mol·h−1 · kg protein−1) 15.2 (3.3) 13.9 (3.7)
Table 4. Endurance-related phenotypes measured after 4 weeks of training: Lactate threshold, VO2 peak, Wpeak, 
Time-trial performance, mitochondrial respiration, and citrate synthase activity for each of the two ACTN3 
genotypes. Values are reported as Mean (SD). No significant difference was demonstrated for any of these 
phenotypes between RR and XX genotypes (p > 0.05).
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In mice, there was no significant difference for the levels of RCAN1-4 protein in KO vs WT animals (1.3 fold 
difference; P = 0.057), but a 2.9-fold greater RCAN1-4 protein content was observed in KO muscle compared 
with WT muscles 3 days after completing an endurance exercise (p = 0.004)14. Consistent with their after-exercise 
RCAN1-4 results14, a 1.9-fold greater calcineurin activity in exercised KO compared with WT muscles was also 
observed, although this difference did not reach statistical significance. Given that our resting muscle biopsies 
were performed 48 to 72 h after prior endurance exercise (a 20-k TT lasting ~ 40 minutes), our results can best be 
compared to the after-exercise results reported by Seto et al.14. In this regard, we also observed a greater RCAN1-4 
protein content in the muscle of ACTN3 577XX versus ACTN3 577RR humans two to three days after exercise 
(1.3 fold; P = 0.004). Despite the main effect of genotype for RCAN1-4 content, there was no significant interac-
tion between genotype and time (i.e., whether our biopsies were taken before or after a session of high-intensity 
interval exercise).
One factor that may have contributed to some of the differences observed between mice and humans is that 
murine muscle contains a significantly higher percentage of fast-twitch fibres compared with human muscle51, 
and the ACTN3 gene is exclusively expressed in fast-twitch skeletal muscles52. The muscles analysed in the 
study by Seto et al.14 contained less than 1% type I fibres, and therefore any effects of α-actinin-3 protein would 
have been enhanced in their mouse model. In line with this hypothesis, exhaustive exercise in rats increased 
RCAN1-4 protein levels in the gastrocnemius, but not the soleus (the gastrocnemius contains a higher per-
centage of fast-twitch fibres compared to soleus)53. Recent studies with single muscle fibres have also observed 
that the greater maximal unloading velocity in the muscle of ACTN3 RR compared to ACTN3 XX genotypes 
likely contributes to enhanced whole-muscle performance during high-velocity contractions54. Future studies 
in single muscle fibres may shed more light on the influence of the ACTN3 gene on human performance and 
exercise-induced cell signalling. It is also worth noting that only men were recruited in the present study, while 
the previous human study only recruited females14. It has previously been reported that the effect of ACTN3 
genotype on endurance performance is more pronounced in female compared with male athletes3. Furthermore, 
the human ACTN3 XX participants in the study of Seto et al.14, that showed increased RCAN1-4 expression 
compared with ACTN3 RR participants (P = 0.004) were quite old (mean age 49 years, with a very large age range 
(33–77 years) and the sample size was small (n = 5). Future research should examine if the effects of ACTN3 gen-
otype are enhanced in both females and aged muscle.
The influence of ACTN3 R577X polymorphism on mitochondrial-related gene expression in 
response to exercise. Based on research with mice reporting a significant effect of ACTN3 genotype on 
training-induced changes in endurance performance, it was hypothesised that ACTN3 genotype would affect 
the exercise-induced increase in nuclear genes encoding mitochondrial proteins. However, despite a signif-
icant exercise-induced increase of all the PGC-1α gene transcripts and PGC-1α protein levels in both geno-
types (p < 0.05), there was no significant main effect for genotype or an interaction effect. Similarly, there was 
no significant main effect for genotype or an interaction effect for the exercise-induced increase of other nuclear 
Figure 6. Mean ± SD for (a) VO2peak, (b) Lactate Threshold (c) Mitochondrial Respiration (d) Citrate Synthase 
activity pre and post 4 weeks high intensity interval training (HIIT) in ACTN3 RR and ACTN3 XX humans.
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genes encoding mitochondrial proteins. These finding are consistent with the absence of a significant difference 
between ACTN3 XX and ACTN3 RR individuals for the exercise-induced elevation of RCAN 1-4 protein content 
(i.e., immediately post and 3 hours post exercise versus baseline).
Exercise-induced changes in some mitochondria-related genes have been reported to be intensity-dependent24 
with greater increases in PGC-1α a mRNA observed after exercise performed at 100% VO2max compared with 
73% VO2max (7.9 vs 4.3 fold55). Based on these previous observations, we chose to investigate the effects of ACTN3 
genotype on changes in mitochondria-related genes in response to a single session of high-intensity interval 
exercise. It is worth noting, however, that calcineurin has been reported to contribute to changes in muscle fibre 
phenotype in response to low-amplitude, sustained calcineurin activity56. Therefore, future research should exam-
ine whether the effects of ACTN3 genotype on exercise-induced changes in calcineurin-related signalling, and 
gene expression, are more pronounced in response to other forms of exercise (e.g., lower-intensity continuous 
exercise).
ACTN3 genotype and training response. Consistent with the gene-expression results, there was no 
effect of genotype on changes in the LT, VO2peak, WPeak, or 20-k TT performance, after four weeks of HIIT. While 
these results contrast with post-training observations after four weeks of continuous exercise training in actn3 KO 
mice14, they are consistent with research that has not identified a relationship between the ACTN3 polymorphism 
and endurance-related phenotypes in humans12,13,42–48. We chose to investigate the effects of ACTN3 genotype 
on physiological adaptations to high-intensity interval training, as this type of training has been reported to be 
equally or more effective than continuous exercise training for improving aerobic fitness (VO2max)57 and pro-
moting mitochondrial adaptations in muscle58. However, future research should examine whether the effects of 
ACTN3 genotype on training-induced changes in physiological parameters differ in response to other forms of 
exercise (e.g., continuous, moderate-intensity exercise) or longer (>4 weeks) exercise-training periods.
conclusions
In conclusion, the results of the present study showed a compensatory increase in α-actinin-2 protein content at 
baseline, with no evidence for a greater adaptive response to a single session of high-intensity interval exercise in 
participants with the ACTN3 XX genotype. This analysis is the first well-powered study in humans to investigate 
potential molecular pathways that might contribute to the hypothesised influence of ACTN3 R577X genotype 
on the response to endurance exercise. These results, combined with the absence of significant differences in 
baseline endurance characteristics, as well as the response to four weeks of exercise training, add to the growing 
body of literature suggesting ACTN3 genotype does not have a major influence on endurance performance or 
the response to endurance training in humans. Despite the absence of significant differences, the use of naturally 
occurring “human knockouts” could still be a useful methodological approach to investigate the role of the loss of 
function of other proteins on the response to exercise in humans.
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